Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Finished Goods (2024 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Finished Goods for 2 consecutive years, with $6.6 million as the latest value for Q4 2025.

  • Quarterly Finished Goods fell 7.84% to $6.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.6 million through Dec 2025, down 7.84% year-over-year, with the annual reading at $6.6 million for FY2025, 7.84% down from the prior year.
  • Finished Goods hit $6.6 million in Q4 2025 for Eton Pharmaceuticals, down from $7.2 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $7.2 million in Q4 2024 to a low of $6.6 million in Q4 2025.